osimertinib mesylate

Osimertinib mesylate (AZD-9291 mesylate) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib mesylate has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.

Rezivertinib analogue 1, a process impurity of osimertinib mesylate, serves as a research tool in the study of non-small cell lung cancer (NSCLC) [1].